Is OPKO Health (OPK) A Bargain As New Results And Guidance Reset Valuation?

OPKO Health (OPK) put fresh numbers on the table this week, pairing its third quarter 2026 results with new revenue guidance for the fourth quarter and full year.

OPKO Health’s earnings update arrived during a strong run in the share price, with the stock now at US$1.73 after a 36.22% year-to-date share price return and a 29.10% total shareholder return over 12 months. However, the 5-year total shareholder return of 58.01% in losses shows long-term holders are still recovering, and recent momentum reflects shifting sentiment around both the revenue outlook and perceived risk following the fresh guidance and results.

Spot fresh momentum in OPKO Health, then broaden your watchlist with a curated set of 19 high quality undiscovered gems that share solid fundamentals yet still fly under most investors’ radar.

Bulls point to OPKO Health’s guidance and revenue trend, while bears focus on the continuing losses and long-term share price damage. Which story does the current valuation actually lean toward?

Most Popular Narrative: 58% Undervalued

On the most followed valuation view, OPKO Health’s fair value of $4.15 sits well above the recent $1.73 share price. This puts the new guidance and pharma focus under a brighter spotlight.

The sale of OPKO Health’s remaining BioReference clinical diagnostics, women’s health, urology, corrections testing businesses and over 80 patient service centers to Labcorp for up to US$872 million in cash and earnouts is expected to further reduce lower margin infrastructure exposure and free capital that can be redeployed into higher margin pharmaceutical and antibody programs, which can support future net margin and earnings improvement.

See why 16 investors see OPKO Health as 58% undervalued.

Result: Fair Value of $4.15 (UNDERVALUED)

Still, the OPKO Health story carries real friction, from ongoing net losses and guided 2026 costs that exceed revenue to heavy reliance on a concentrated set of partnered assets.

Find out about the key risks to this OPKO Health narrative.

Another View: What OPKO Health’s P/S Ratio Signals

The fair value story points to OPKO Health looking 58% undervalued at $4.15 per share. A simple reality check using the P/S ratio tells a very different story. OPKO Health trades on roughly 2x sales, while US Healthcare peers average about 1.2x and the fair ratio for this stock is estimated at just 0.5x. That gap suggests investors are already paying up for a business that is still loss making, which raises a practical question for you. Is the potential upside in the bullish narrative big enough to justify paying a premium multiple today?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Curious whether the optimism around OPKO Health really stacks up for you personally, or feels a step ahead of the fundamentals? Move quickly, review the details, and weigh both upside and downside by checking the 2 important warning signs.

Looking for more OPKO Health investment ideas?

Do not stop at OPKO Health alone. Use curated screeners to find other shares that fit your style before the next wave of opportunities gets crowded.

This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include OPK.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]